Selecta Biosciences. has filed a patent for a method involving dosing viral vectors with synthetic nanocarriers attached to an immunosuppressant to reduce immune responses and enhance gene expression. The method aims to improve therapeutic outcomes in subjects. GlobalData’s report on Selecta Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Selecta Biosciences, Nanoparticle drug conjugates was a key innovation area identified from patents. Selecta Biosciences's grant share as of January 2024 was 20%. Grant share is based on the ratio of number of grants to total number of patents.
Enhanced gene therapy using viral vectors and immunosuppressants
The patent application (Publication Number: US20240024517A1) describes a method for administering viral vectors and synthetic nanocarriers attached to immunosuppressants to reduce undesired immune responses and enhance gene expression in subjects. The method involves a series of dosings, including a first dosing with both viral vectors and synthetic nanocarriers, a second dosing with only synthetic nanocarriers, and potentially a third dosing with synthetic nanocarriers. These dosings are administered according to a specific schedule to achieve the desired immune response reduction and gene expression enhancement, lasting for at least one to three months from the initial dosing.
Furthermore, the patent application also includes a composition comprising different doses of viral vectors and synthetic nanocarriers attached to immunosuppressants, housed in a kit for convenient administration. The composition may also include a pharmaceutically acceptable carrier. The immunosuppressants mentioned in the claims include various agents like statins, mTOR inhibitors, corticosteroids, and others. The method is particularly relevant for treating conditions like methylmalonic acidemia (MMA) or ornithine transcarbamylase (OTC) deficiency using AAV vectors, such as AAV8 vectors. The synthetic nanocarriers are described as polymeric with specific particle size distributions and aspect ratios to optimize their effectiveness in reducing immune responses and enhancing gene expression.
To know more about GlobalData’s detailed insights on Selecta Biosciences, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
